Misryoum reports how renewed research into glycol vapors could help reduce airborne disease spread and prepare for future outbreaks.
Airborne outbreaks may be the next major health threat, but one overlooked idea is being revisited: the kind of “old tech” that could help disinfect indoor air.
Glycol compounds, widely used in everyday products like textiles and bottles, have long been part of industrial life.. Now Misryoum reports that research is looking at a specific property of glycol vapors: when released into indoor air. they may inactivate some viruses. bacteria. and fungal spores while remaining effectively invisible and odorless at low concentrations.. The focus is on whether this approach could reduce transmission of illnesses that spread through the air. including seasonal flu and. potentially. the next pandemic.
The prospect is attracting attention because it targets a problem people cannot avoid: what they breathe indoors. If the science holds up, it could complement ventilation and filtration rather than asking individuals to “opt in” with personal protective measures.
Interest in glycol vapors for infection prevention is not new.. Earlier studies in mid-20th-century hospital settings suggested reductions in respiratory illnesses when glycol vapors were used in wards.. That line of inquiry faded over time. in part as antibiotics transformed how clinicians treated infections and as other disinfection methods became more common.
Misryoum says the COVID-19 era brought renewed attention, including emergency regulatory approvals for certain glycol-based products in some settings.. Yet the broader scientific picture remained limited. and public health messaging during the early pandemic prioritized measures that were easier to understand and widely adopted.. The question now is whether glycol vapors can offer reliable. real-world benefits against airborne pathogens while maintaining an acceptable safety profile.
This matters because airborne diseases create ripple effects beyond health—missed work and school, strain on hospitals, and long-term consequences for patients and families. Tools that can reduce spread in shared indoor spaces could help blunt those impacts when outbreaks begin.
Blueprint Biosecurity is now funding additional research under Misryoum coverage. with projects aimed at understanding how glycol vapors work. how they perform in emergency-style deployment. and how they interact with heating. ventilation. and filtration systems.. Investigators also plan to examine safety considerations. including potential effects on people with more sensitive respiratory conditions such as asthma. as well as whether glycol vapor use could create unintended chemistry in indoor environments.
Researchers say early findings are expected in the coming years. with work that includes testing in controlled environments and then moving toward more representative occupied settings once appropriate regulatory steps are completed.. Misryoum notes that this process reflects a wider lesson from the pandemic era: promising ideas still require careful validation before they can become public health policy.
Finally, even if glycol vapors ultimately prove effective, adoption will depend on trust and clear regulatory guidance. The goal, as Misryoum frames it, is to build a multilayered approach to indoor safety so that communities are not starting from scratch when the next airborne threat emerges.